Zacks: DiaMedica Therapeutics Inc (DMAC) Receives Average Recommendation of “Strong Buy” from Analysts

Shares of DiaMedica Therapeutics Inc (NASDAQ:DMAC) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a twelve-month consensus target price of $14.10 for the company, according to Zacks. Zacks has also assigned DiaMedica Therapeutics an industry rank of 77 out of 255 based on the ratings given to its competitors.

Several equities analysts have recently commented on DMAC shares. Lake Street Capital started coverage on shares of DiaMedica Therapeutics in a research note on Tuesday, March 5th. They set a “buy” rating and a $9.00 price objective for the company. Craig Hallum started coverage on shares of DiaMedica Therapeutics in a research note on Thursday, January 3rd. They set a “buy” rating for the company.

A hedge fund recently bought a new stake in DiaMedica Therapeutics stock. Worth Venture Partners LLC purchased a new position in DiaMedica Therapeutics Inc (NASDAQ:DMAC) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 129,863 shares of the company’s stock, valued at approximately $377,000. Worth Venture Partners LLC owned approximately 1.09% of DiaMedica Therapeutics at the end of the most recent reporting period. 8.64% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:DMAC opened at $3.10 on Tuesday. DiaMedica Therapeutics has a 12 month low of $2.46 and a 12 month high of $4.25.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.

Read More: Backdoor Roth IRA

Get a free copy of the Zacks research report on DiaMedica Therapeutics (DMAC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with's FREE daily email newsletter.